Melinda L. Telli, Manuel Ruiz-Borrego, Kan Yonemori, Yanxia Zhao, Komal L. Jhaveri, Shusen Wang, Amita Patnaik, Jean-Sebastien Frenel, Ping Xu, Lana Tran, Shaparak Lonning, Noah C. Berkowitz, Yuanyuan Zhang, Marco Mazzoletti, Toru Mukohara. "Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2− advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1075